Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34608129/

To investigate the efficacy and toxicities of CPX-351 outside a clinical trial, we analyzed 188 patients (median age 65 years, range 26-80) treated for therapy-related acute myeloid leukemia (t-AML, 29%)...

Application of Next-Generation Sequencing-Based Mutational Profiling in Acute Lymphoblastic Leukemia - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34613552/

NGS-based assessment of measurable residual disease (MRD) after ALL treatment allows for a sensitive and specific molecular survey that is at least comparable, if not superior, to existing techniques. Mutational...

Early Detection of WT1 Measurable Residual Disease Identifies High-Risk Patients Independently of Transplantation in AML - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34625784/

WT1 overexpression is frequently identified in acute myeloid leukemia (AML) and has been reported as a potential marker for measurable residual disease (MRD) monitoring. Here, we evaluated the value of...

Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34633671/

doi: 10.1002/cncr.33967. Online ahead of print. 1 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California. 2 Department of Computational and Quantitative Medicine, City...

Complete eradication of chronic lymphocytic leukemia with unusual skin involvement of high mitotic index after time-limited venetoclax/obinutuzumab treatment - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34322260/

The novel time-limited combinations with the bcl-2 inhibitor venetoclax can induce deep responses even in CLL cases with unusual and biologically aggressive presentations, like the skin masses of our patient....